U.S. market Closed. Opens in 9 hours 26 minutes

TEVA | Teva Pharmaceutical Industries Limited Stock Fundamentals

(Stock Exchange: NYSE)
Analyzing fundamentals for TEVA we got that it has weak fundamentals where Valuation is considered to be slightly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak.

Valuation (45%)

Company Industry
P/E Ratio (TTM) -25.66 11.75
PEG Ratio (TTM) 0.37 1.21
P/S Ratio (TTM) 1.52 4.50
P/B Ratio (TTM) 4.20 3.43
P/FCF Ratio (TTM) 18.65 25.09
Price to 5YR AVG Earnings Ratio -16.39 29.82
Price to 5YR AVG FCF Ratio 39.81 19.41

Profitability (5%)

Company Industry
ROA (TTM) -2.38% 3.20%
ROE (TTM) -14.60% 9.93%
Net Profit Margin (TTM) -5.92% -14.36%
ROIC 5YR AVG 7.86% 8.75%

Growth (23%)

4QTR AVG 3YR AVG 5YR AVG
EPS -33.01% -42.94% -142.06%
Revenue 3.61% -5.49% -3.26%
Net Income -38.95% -45.14% -144.69%
Cash Flow 5,926.26% 4.55% 19.79%

Health (19%)

Company Industry
Current Ratio (TTM) 0.89 2.47
Quick Ratio (TTM) 0.61 1.84
D/E Ratio (TTM) 3.13 -0.08
Interest Coverage (TTM) 0.44 15.92
Piotroski F-Score 5 6
Altman Z-Score 0.34 4.53
LTL to 5YR AVG FCF 29.09 5.15
Shares Outstanding Growth 5YR AVG 1.88% 28.45%
An error has occurred. This application may no longer respond until reloaded. Reload 🗙